Stockreport

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025 [Yahoo! Finance]

Acorda Therapeutics, Inc.  (ACOR) 
Last acorda therapeutics, inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acorda.com/investors
PDF rights to FAMPYRA ® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement between the companies, effective January 1, 2025. FA [Read more]